Defining the Value of a Comparative Approach to Cancer Drug Development
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Comparative oncology as a tool in drug development requires a deeper examination of the value of the approach and examples of where this approach can satisfy unmet needs. This review seeks to demonstrate types of drug development questions that are best answered by the comparative oncology approach. We believe common perceived risks of the comparative approach relate to uncertainty of how regulatory bodies will prioritize or react to data generated from these unique studies conducted in diseased animals, and how these new data will affect ongoing human clinical trials. We contend that it is reasonable to consider these data as potentially informative and valuable to cancer drug development, but as supplementary to conventional preclinical studies and human clinical trials particularly as they relate to the identification of drug-associated adverse events. Clin Cancer Res; 22(9); 2133–8. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561 · cited 1×
“Validation of the fluorescently labeled derivative of ibrutinib to monitor occupancy of Btk by the drug has led to adoption of this approach as pharmacodynamic readout in subsequent human trials, while also supporting the use of ibrutinib in humans with B-cell malignancies (12, 13).”
ResultCanine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
Paoloni, M., Davis, S., Lana, S., Withrow, S., Sangiorgi, L., Picci, P., Hewitt, S., Triche, T., Meltzer, P., & Khanna, C. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-625 · Cited by 291 · cited 1×
“In one such example, candidate genes IL8 and SLC1A3 were identified in canine osteosarcoma as overexpressed; these same genes had variable expression in human osteosarcoma but nevertheless were associated with a poor clinical outcome (16).”
BackgroundSelf-citationToward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2574 · Cited by 178
Self-citation
Cited by
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology
LeBlanc, A. K., Breen, M., Choyke, P., Dewhirst, M., Fan, T. M., Gustafson, D. L., Helman, L. J., Kastan, M. B., Knapp, D. W., Levin, W. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0746 · Cited by 147
“To address issue (iii), a recent manuscript now provides additional clarity on the value of comparative oncology studies (10).”
BackgroundSelf-citationCanine Cancer: Strategies in Experimental Therapeutics
Thamm, D. H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01257 · Cited by 38
Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
Brady, R. V., & Thamm, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176807 · Cited by 35
“Companion dogs are a strong comparative immunooncology model for people due to documented similarities of the immune system and spontaneous cancers between the species (14).”
Background
Metadata
- Authors
- LeBlanc, A. K., Mazcko, C. N., & Khanna, C.
- Venue
- Clinical Cancer Research
- Published
- 2016-05-01
- Volume
- 22
- Issue
- 9
- Pages
- 2133-2138
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2201086533
- Cited by
- 73
- References
- 3
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining the Value of a Comparative Approach to Cancer Drug Development. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2347
- The paper
- LeBlanc, A. K., Mazcko, C. N., & Khanna, C. (2016). Defining the Value of a Comparative Approach to Cancer Drug Development. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.